Recruiting

BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

ClinicalTrials.gov IDNCT06913712

PhaseNot Applicable

Enrollment25

SponsorUniversity of Valencia

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Idiopathic Intracranial Hypertension (IIH)

About this study

Interventions

Other: Weight loss without pharmacotherapy — The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.

Primary outcomes

Response to treatment (Through study completion, an average of 1 year)

Eligibility information

Inclusion Criteria: * Adults aged 18 years and older at the time of enrollment. There is no upper age limit to ensure inclusivity across age ranges. * A confirmed diagnosis of Idiopathic Intracranial Hypertension, established according to the Dandy criteria. * The diagnostic process must exclude other potential causes of increased intracranial pressure as detailed in the 'Diagnosis' section, ensuring an accurate identification of idiopathic cases. Exclusion Criteria: * A diagnosis other than IIH, specifically: tension-type headache, Chiari I malformation, or any other headache disorder unrelated to IIH. * The presence of secondary causes of increased intracranial pressure (e.g., structural brain abnormalities, venous sinus thrombosis, or medication-induced factors).

Study locations

Consorcio Hospital General Universitario de Valencia, Valencia, Valencia 46015 Spain

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.